Fig. 6

SAS proteins are highly modulated by selonsertib in patients with low baseline eGFR. Trial participants were grouped based on baseline eGFR levels and the mean change in biomarker levels between the end of the study (week 48) and baseline was plotted for selonsertib and placebo to match (PTM) cohorts separately